Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: A single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China
Objectives: To compare immunogenicity among an inactivated hepatitis A vaccine (Healive ® ) with one-dose and two-dose regimens, and three kinds of live attenuated vaccines in children. Results: No significant differences were observed in seroconversion rates (seroprotection rates) among the five gr...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2013-07, Vol.9 (7), p.1460-1465 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1465 |
|---|---|
| container_issue | 7 |
| container_start_page | 1460 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 9 |
| creator | Liu, Xue-en Wushouer, Fuerhati Gou, Aili Kuerban, Mahemuti Li, Xinlan Sun, Yubo Zhang, Jiamin Liu, Yan Li, Jie Zhuang, Hui |
| description | Objectives: To compare immunogenicity among an inactivated hepatitis A vaccine (Healive
®
) with one-dose and two-dose regimens, and three kinds of live attenuated vaccines in children.
Results: No significant differences were observed in seroconversion rates (seroprotection rates) among the five groups at 6 or 12 mo (p > 0.05). The geometric mean concentration (GMC) of anti-HAV IgG was significantly higher in the two-dose Healive
®
group than in the one-dose Healive
®
group and the attenuated vaccine groups at 12 mo (932.4 vs. 112.7, 135.8, 203.3, 212.8 mIU/ml, respectively, p < 0.05). In the one-dose Healive
®
group, the GMC was significantly lower than that in the attenuated vaccine B and C groups at 6 mo (152.6 vs. 212, 204 mIU/ml, p < 0.05) and at 12 mo (112.7 vs. 203.3, 212.8, p < 0.05), but was similar to the attenuated vaccine A group at 12 mo (112.7 vs. 135.8 mIU/ml, p > 0.05). The GMCs were significantly higher in the 1-2 y of age group than in the 3-6 y of age group for all types of vaccines except the attenuated vaccine C (p < 0.05) at 12 mo.
Methods: A single-blind, randomized, parallel-group clinical trial was conducted among healthy children aged 1.5-6 y in Xinjiang Uighur Autonomous Region, China. Subjects were randomly assigned to 5 groups. Two groups were administered one-dose or two-dose inactivated vaccine and the remaining groups were immunized with one of three kinds of attenuated vaccines, respectively. Serum samples were collected at 6- and 12-mo follow-ups. Anti-HAV IgG was measured with a microparticle enzyme immunoassay.
Conclusions: A higher GMC of anti-HAV IgG was induced in the two-dose Healive
®
than in the one-dose and the attenuated vaccines at 12 mo. The attenuated vaccine B or C produced higher GMCs than the one-dose Healive
®
at 6-12 mo after vaccination. |
| doi_str_mv | 10.4161/hv.24366 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23571173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1443396028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-ccef199778ac0cf5e59ea68ee5f67c3fb1d8d63f66cc7d538f2fe086b0d7aea73</originalsourceid><addsrcrecordid>eNplkE1LAzEQQIMotlTBXyA5eqluNrvJ9liKX1DwoqCnMJud2MhuUpPsSv-91Wo9OJcZhsc7PELOWHZZMMGuVsNlXnAhDsg4Z6KYlmXxfLi_WTkipzG-ZduRWV4IcUxGOS8lY5KPycvCd2sINnpHvaG263rnX9FZbdOG1pg-EB21DnSyAyRsKLiGtnZACimh679_K1xDsslGOqcDaG0dxhNyZKCNePqzJ-Tp5vpxcTddPtzeL-bLqc6rKk21RsNmMykr0Jk2JZYzBFEhlkZIzU3NmqoR3AihtWxKXpncYFaJOmskIEg-IRc77zr49x5jUp2NGtsWHPo-KlYUnM9Elld_qA4-xoBGrYPtIGwUy9RXS7Ua1HfLLXr-Y-3rDps9-FtuC_AdYJ3xoYMPH9pGJdi0PpgATtuo-D_tJymlgq8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443396028</pqid></control><display><type>article</type><title>Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: A single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Liu, Xue-en ; Wushouer, Fuerhati ; Gou, Aili ; Kuerban, Mahemuti ; Li, Xinlan ; Sun, Yubo ; Zhang, Jiamin ; Liu, Yan ; Li, Jie ; Zhuang, Hui</creator><creatorcontrib>Liu, Xue-en ; Wushouer, Fuerhati ; Gou, Aili ; Kuerban, Mahemuti ; Li, Xinlan ; Sun, Yubo ; Zhang, Jiamin ; Liu, Yan ; Li, Jie ; Zhuang, Hui</creatorcontrib><description>Objectives: To compare immunogenicity among an inactivated hepatitis A vaccine (Healive
®
) with one-dose and two-dose regimens, and three kinds of live attenuated vaccines in children.
Results: No significant differences were observed in seroconversion rates (seroprotection rates) among the five groups at 6 or 12 mo (p > 0.05). The geometric mean concentration (GMC) of anti-HAV IgG was significantly higher in the two-dose Healive
®
group than in the one-dose Healive
®
group and the attenuated vaccine groups at 12 mo (932.4 vs. 112.7, 135.8, 203.3, 212.8 mIU/ml, respectively, p < 0.05). In the one-dose Healive
®
group, the GMC was significantly lower than that in the attenuated vaccine B and C groups at 6 mo (152.6 vs. 212, 204 mIU/ml, p < 0.05) and at 12 mo (112.7 vs. 203.3, 212.8, p < 0.05), but was similar to the attenuated vaccine A group at 12 mo (112.7 vs. 135.8 mIU/ml, p > 0.05). The GMCs were significantly higher in the 1-2 y of age group than in the 3-6 y of age group for all types of vaccines except the attenuated vaccine C (p < 0.05) at 12 mo.
Methods: A single-blind, randomized, parallel-group clinical trial was conducted among healthy children aged 1.5-6 y in Xinjiang Uighur Autonomous Region, China. Subjects were randomly assigned to 5 groups. Two groups were administered one-dose or two-dose inactivated vaccine and the remaining groups were immunized with one of three kinds of attenuated vaccines, respectively. Serum samples were collected at 6- and 12-mo follow-ups. Anti-HAV IgG was measured with a microparticle enzyme immunoassay.
Conclusions: A higher GMC of anti-HAV IgG was induced in the two-dose Healive
®
than in the one-dose and the attenuated vaccines at 12 mo. The attenuated vaccine B or C produced higher GMCs than the one-dose Healive
®
at 6-12 mo after vaccination.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.4161/hv.24366</identifier><identifier>PMID: 23571173</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antibody Formation ; Child ; Child, Preschool ; China ; Female ; Hepatitis A - immunology ; Hepatitis A - prevention & control ; Hepatitis A Antibodies - blood ; Hepatitis A Vaccines - adverse effects ; Hepatitis A Vaccines - immunology ; Hepatitis A Vaccines - therapeutic use ; Humans ; Immunization Schedule ; immunogenicity ; Immunoglobulin G - immunology ; inactivated hepatitis A vaccine ; Infant ; live attenuated hepatitis A vaccine ; Male ; Single-Blind Method ; Vaccination ; Vaccines, Attenuated - immunology ; Vaccines, Attenuated - therapeutic use ; Vaccines, Inactivated - immunology ; Vaccines, Inactivated - therapeutic use</subject><ispartof>Human vaccines & immunotherapeutics, 2013-07, Vol.9 (7), p.1460-1465</ispartof><rights>Copyright © 2013 Landes Bioscience 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c288t-ccef199778ac0cf5e59ea68ee5f67c3fb1d8d63f66cc7d538f2fe086b0d7aea73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23571173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Xue-en</creatorcontrib><creatorcontrib>Wushouer, Fuerhati</creatorcontrib><creatorcontrib>Gou, Aili</creatorcontrib><creatorcontrib>Kuerban, Mahemuti</creatorcontrib><creatorcontrib>Li, Xinlan</creatorcontrib><creatorcontrib>Sun, Yubo</creatorcontrib><creatorcontrib>Zhang, Jiamin</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Zhuang, Hui</creatorcontrib><title>Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: A single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Objectives: To compare immunogenicity among an inactivated hepatitis A vaccine (Healive
®
) with one-dose and two-dose regimens, and three kinds of live attenuated vaccines in children.
Results: No significant differences were observed in seroconversion rates (seroprotection rates) among the five groups at 6 or 12 mo (p > 0.05). The geometric mean concentration (GMC) of anti-HAV IgG was significantly higher in the two-dose Healive
®
group than in the one-dose Healive
®
group and the attenuated vaccine groups at 12 mo (932.4 vs. 112.7, 135.8, 203.3, 212.8 mIU/ml, respectively, p < 0.05). In the one-dose Healive
®
group, the GMC was significantly lower than that in the attenuated vaccine B and C groups at 6 mo (152.6 vs. 212, 204 mIU/ml, p < 0.05) and at 12 mo (112.7 vs. 203.3, 212.8, p < 0.05), but was similar to the attenuated vaccine A group at 12 mo (112.7 vs. 135.8 mIU/ml, p > 0.05). The GMCs were significantly higher in the 1-2 y of age group than in the 3-6 y of age group for all types of vaccines except the attenuated vaccine C (p < 0.05) at 12 mo.
Methods: A single-blind, randomized, parallel-group clinical trial was conducted among healthy children aged 1.5-6 y in Xinjiang Uighur Autonomous Region, China. Subjects were randomly assigned to 5 groups. Two groups were administered one-dose or two-dose inactivated vaccine and the remaining groups were immunized with one of three kinds of attenuated vaccines, respectively. Serum samples were collected at 6- and 12-mo follow-ups. Anti-HAV IgG was measured with a microparticle enzyme immunoassay.
Conclusions: A higher GMC of anti-HAV IgG was induced in the two-dose Healive
®
than in the one-dose and the attenuated vaccines at 12 mo. The attenuated vaccine B or C produced higher GMCs than the one-dose Healive
®
at 6-12 mo after vaccination.</description><subject>Antibody Formation</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>China</subject><subject>Female</subject><subject>Hepatitis A - immunology</subject><subject>Hepatitis A - prevention & control</subject><subject>Hepatitis A Antibodies - blood</subject><subject>Hepatitis A Vaccines - adverse effects</subject><subject>Hepatitis A Vaccines - immunology</subject><subject>Hepatitis A Vaccines - therapeutic use</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>immunogenicity</subject><subject>Immunoglobulin G - immunology</subject><subject>inactivated hepatitis A vaccine</subject><subject>Infant</subject><subject>live attenuated hepatitis A vaccine</subject><subject>Male</subject><subject>Single-Blind Method</subject><subject>Vaccination</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccines, Attenuated - therapeutic use</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Inactivated - therapeutic use</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkE1LAzEQQIMotlTBXyA5eqluNrvJ9liKX1DwoqCnMJud2MhuUpPsSv-91Wo9OJcZhsc7PELOWHZZMMGuVsNlXnAhDsg4Z6KYlmXxfLi_WTkipzG-ZduRWV4IcUxGOS8lY5KPycvCd2sINnpHvaG263rnX9FZbdOG1pg-EB21DnSyAyRsKLiGtnZACimh679_K1xDsslGOqcDaG0dxhNyZKCNePqzJ-Tp5vpxcTddPtzeL-bLqc6rKk21RsNmMykr0Jk2JZYzBFEhlkZIzU3NmqoR3AihtWxKXpncYFaJOmskIEg-IRc77zr49x5jUp2NGtsWHPo-KlYUnM9Elld_qA4-xoBGrYPtIGwUy9RXS7Ua1HfLLXr-Y-3rDps9-FtuC_AdYJ3xoYMPH9pGJdi0PpgATtuo-D_tJymlgq8</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Liu, Xue-en</creator><creator>Wushouer, Fuerhati</creator><creator>Gou, Aili</creator><creator>Kuerban, Mahemuti</creator><creator>Li, Xinlan</creator><creator>Sun, Yubo</creator><creator>Zhang, Jiamin</creator><creator>Liu, Yan</creator><creator>Li, Jie</creator><creator>Zhuang, Hui</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines</title><author>Liu, Xue-en ; Wushouer, Fuerhati ; Gou, Aili ; Kuerban, Mahemuti ; Li, Xinlan ; Sun, Yubo ; Zhang, Jiamin ; Liu, Yan ; Li, Jie ; Zhuang, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-ccef199778ac0cf5e59ea68ee5f67c3fb1d8d63f66cc7d538f2fe086b0d7aea73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antibody Formation</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>China</topic><topic>Female</topic><topic>Hepatitis A - immunology</topic><topic>Hepatitis A - prevention & control</topic><topic>Hepatitis A Antibodies - blood</topic><topic>Hepatitis A Vaccines - adverse effects</topic><topic>Hepatitis A Vaccines - immunology</topic><topic>Hepatitis A Vaccines - therapeutic use</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>immunogenicity</topic><topic>Immunoglobulin G - immunology</topic><topic>inactivated hepatitis A vaccine</topic><topic>Infant</topic><topic>live attenuated hepatitis A vaccine</topic><topic>Male</topic><topic>Single-Blind Method</topic><topic>Vaccination</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccines, Attenuated - therapeutic use</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Inactivated - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Xue-en</creatorcontrib><creatorcontrib>Wushouer, Fuerhati</creatorcontrib><creatorcontrib>Gou, Aili</creatorcontrib><creatorcontrib>Kuerban, Mahemuti</creatorcontrib><creatorcontrib>Li, Xinlan</creatorcontrib><creatorcontrib>Sun, Yubo</creatorcontrib><creatorcontrib>Zhang, Jiamin</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Zhuang, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Xue-en</au><au>Wushouer, Fuerhati</au><au>Gou, Aili</au><au>Kuerban, Mahemuti</au><au>Li, Xinlan</au><au>Sun, Yubo</au><au>Zhang, Jiamin</au><au>Liu, Yan</au><au>Li, Jie</au><au>Zhuang, Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: A single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>9</volume><issue>7</issue><spage>1460</spage><epage>1465</epage><pages>1460-1465</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Objectives: To compare immunogenicity among an inactivated hepatitis A vaccine (Healive
®
) with one-dose and two-dose regimens, and three kinds of live attenuated vaccines in children.
Results: No significant differences were observed in seroconversion rates (seroprotection rates) among the five groups at 6 or 12 mo (p > 0.05). The geometric mean concentration (GMC) of anti-HAV IgG was significantly higher in the two-dose Healive
®
group than in the one-dose Healive
®
group and the attenuated vaccine groups at 12 mo (932.4 vs. 112.7, 135.8, 203.3, 212.8 mIU/ml, respectively, p < 0.05). In the one-dose Healive
®
group, the GMC was significantly lower than that in the attenuated vaccine B and C groups at 6 mo (152.6 vs. 212, 204 mIU/ml, p < 0.05) and at 12 mo (112.7 vs. 203.3, 212.8, p < 0.05), but was similar to the attenuated vaccine A group at 12 mo (112.7 vs. 135.8 mIU/ml, p > 0.05). The GMCs were significantly higher in the 1-2 y of age group than in the 3-6 y of age group for all types of vaccines except the attenuated vaccine C (p < 0.05) at 12 mo.
Methods: A single-blind, randomized, parallel-group clinical trial was conducted among healthy children aged 1.5-6 y in Xinjiang Uighur Autonomous Region, China. Subjects were randomly assigned to 5 groups. Two groups were administered one-dose or two-dose inactivated vaccine and the remaining groups were immunized with one of three kinds of attenuated vaccines, respectively. Serum samples were collected at 6- and 12-mo follow-ups. Anti-HAV IgG was measured with a microparticle enzyme immunoassay.
Conclusions: A higher GMC of anti-HAV IgG was induced in the two-dose Healive
®
than in the one-dose and the attenuated vaccines at 12 mo. The attenuated vaccine B or C produced higher GMCs than the one-dose Healive
®
at 6-12 mo after vaccination.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>23571173</pmid><doi>10.4161/hv.24366</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2013-07, Vol.9 (7), p.1460-1465 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_23571173 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibody Formation Child Child, Preschool China Female Hepatitis A - immunology Hepatitis A - prevention & control Hepatitis A Antibodies - blood Hepatitis A Vaccines - adverse effects Hepatitis A Vaccines - immunology Hepatitis A Vaccines - therapeutic use Humans Immunization Schedule immunogenicity Immunoglobulin G - immunology inactivated hepatitis A vaccine Infant live attenuated hepatitis A vaccine Male Single-Blind Method Vaccination Vaccines, Attenuated - immunology Vaccines, Attenuated - therapeutic use Vaccines, Inactivated - immunology Vaccines, Inactivated - therapeutic use |
| title | Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: A single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A17%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20immunogenicity%20between%20inactivated%20and%20live%20attenuated%20hepatitis%20A%20vaccines:%20A%20single-blind,%20randomized,%20parallel-group%20clinical%20trial%20among%20children%20in%20Xinjiang%20Uighur%20Autonomous%20Region,%20China&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Liu,%20Xue-en&rft.date=2013-07-01&rft.volume=9&rft.issue=7&rft.spage=1460&rft.epage=1465&rft.pages=1460-1465&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.4161/hv.24366&rft_dat=%3Cproquest_pubme%3E1443396028%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443396028&rft_id=info:pmid/23571173&rfr_iscdi=true |